

**FIBROBIOLOGICS, INC.**  
455 E. Medical Center Blvd.  
Suite 300  
Houston, Texas 77598

January 22, 2024

**VIA EDGAR**

Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549  
Division of Corporation Finance  
Office of Life Sciences

Attention: Tim Buchmiller  
Cindy Polynice  
Joe McCann

**RE: FibroBiologics, Inc. (the "Company")  
Registration Statement on Form S-1  
File No. 333-275361**

Dear Mr. Buchmiller, Ms. Polynice and Mr. McCann:

Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, the Company hereby respectfully requests that the effective date of the Company's Registration Statement on Form S-1 (File No. 333-275361) be accelerated by the Securities and Exchange Commission to 4:00 p.m. Washington D.C. time on January 24, 2024, or as soon as practicable thereafter, unless the Company notifies you otherwise prior to such time.

We request that we be notified of such effectiveness by a telephone call to Brian Fenske at (713) 651-5557 or Lee McIntyre at (713) 651-5328 of Norton Rose Fulbright (US) LLP, and that such effectiveness also be confirmed in writing.

Very truly yours,

FibroBiologics, Inc.

By: /s/ Pete O'Heeran

Name: Pete O'Heeran

Title: Chief Executive Officer

---